IN B012
Alternative Names: IN-B012Latest Information Update: 21 Jan 2022
At a glance
- Originator HK inno.N
- Class Anti-inflammatories; Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Irritable bowel syndrome
Most Recent Events
- 01 Jan 2022 Preclinical trials in Inflammatory bowel diseases in South Korea (unspecified route) (HK inno.N Pipeline, January 2022)
- 01 Jan 2022 Preclinical trials in Irritable bowel syndrome in South Korea (unspecified route) (HK inno.N Pipeline, January 2022)
- 20 Apr 2021 IN B012 is available for licensing as of 20 Apr 2021. http://www.inno-n.com/eng/business/out_licensing.asp